<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="880">
  <stage>Registered</stage>
  <submitdate>14/11/2005</submitdate>
  <approvaldate>15/11/2005</approvaldate>
  <actrnumber>ACTRN12605000742673</actrnumber>
  <trial_identification>
    <studytitle>AVX754 (nucleoside reverse transcriptase inhibitor) to treat drug resistant HIV</studytitle>
    <scientifictitle>A Phase II, randomised, double-blinded, dose ranging study of AVX754 to reduce the viral load versus lamivudine in treatment experienced HIV-1 infected patients with the M184V mutation in reverse transcriptase.</scientifictitle>
    <utrn />
    <trialacronym>AVX-201</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>HIV Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>600mg or 800mg AVX754 (a new drug treatment of HIV) for 48 weeks.

This study is a phase IIb randomised, double-blind, multi-centre, dose-ranging, controlled parallel group study where lamivudine is the comparator. The study will enrol approximately 60 patients who will be followed for 48 weeks. The study will measure how safe and effective two doses of AVX754 (a new drug for the treatment of HIV) (600mg or 800mg) is compared to 150mg of lamivudine in treating HIV-1 infected people who have failed treatment with lamivudine.</interventions>
    <comparator>150mg Lamivudine for 48 weeks.</comparator>
    <control>Active</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate the antiretroviral activity</outcome>
      <timepoint>After 21 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Viral dynamic of two doses of AVX754 versus lamivudine in treatment of experienced subjects who are HIV-1 positive with the M184V mutation in reverse transcriptase.</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To evaluate the safety of AVX754 in HIV-1 treatment experienced subjects.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in HIV RNA levels</outcome>
      <timepoint>At days 7, 14 and 21.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with HIV RNA levels &lt;400 or &lt;50</outcome>
      <timepoint>At days 7, 14, 21 and weeks 24 and 48.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline and change in ratio of CD4+ and CD8+ cells</outcome>
      <timepoint>At day 21, Wk 24 and 48.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Informed consentHIV-1 infectedM184V mutation in reverse transcriptaseCurrently taking lamivudineViral load &gt;2,000 copies/mlCD4+ T-cell count&gt;50 cells.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Hep B surface Antigen PositivePregnant or breast feeding femalesHepatitis C RNA positive requiring treatment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by fax.  The study investigators and patients are blinded to randomisation allocation.</concealment>
    <sequence>Randomisation schedule is generated by computer software that incorporates a standard procedure for generating randomisation codes.  Subjects randomised in a 1:1:1 ratio.  Two-part computer-generated labels are used to blind the investigational product.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>7/06/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Avexa Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Avexa Ltd</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Avexa Ltd</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincents Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Albion Street Clinic</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prahran Market Clinic</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Carlton Clinic</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Gold Coast Sexual Health Clinic</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Susan Cox</name>
      <address>Avexa
576 Swan St
Richmond VIC 3121</address>
      <phone>+61 3 92084300</phone>
      <fax>+61 3 92084004</fax>
      <email>scox@avexa.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Susan Cox</name>
      <address>Avexa
576 Swan St
Richmond VIC 3121</address>
      <phone>+61 3 92084300</phone>
      <fax>+61 3 92084004</fax>
      <email>scox@avexa.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>